Bli medlem
Bli medlem

Du är här


Immunicum AB: Immunicum AB Announces Hiring New Investor Relations Firm

Gothenburg, Sweden, March 14, 2016 - Immunicum AB (publ), striving to develop
sophisticated, safe and efficient therapeutic cancer treatments with powerful
and long lasting immune responses,
today announced that the Company has engaged The Blueshirt Group to assist
Immunicum in developing its communication and investor outreach program with
the global financial community.

"Our strategy is to partner with The Blueshirt Group to help us expand our
presence in the international investment community and communicate our
increasing development efforts", said Jamal El-Mosleh, Chief Executive
Officer of Immunicum. "We are looking forward to leveraging The Blueshirt
Group's and Julie Silbe's extensive experience in working with healthcare,
biotech and pharma companies as we enter the next stage of our Company's

"This is a great opportunity to work with an advancing biotech company in the
cancer treatment space and we are excited to help the investment community
better understand Immunicum's strategy and opportunity," said Julie Silber,
Managing Director of the European office of The Blueshirt Group. "With the
on-going announcements from the successes of the clinical trials, the
potential market size and the positive results with liver cancer patients and
kidney cancer patients, we expect that the interest from the financial
community will continue to expand and we are delighted to be here as part of
the Immunicum team."

For further information, please contact:

Julie Silber, Investor Relations
Telephone: +46 (0)7 93 486 277, Europe
Telephone: +1 310 766 9760, North America

About Immunicum AB (publ)

Immunicum AB (publ) is working to develop and advance cancer immune primers
for the treatment of tumor diseases. A clinical phase II trial for the
Company's most advanced product - INTUVAX® against kidney cancer - has been
initiated. The project portfolio contains additional clinical phase I/II
studies in liver cancer in gastrointestinal stromal tumors (GIST). The
Company's current lead project is INTUVAX, a cancer immune primer, developed
for the treatment of solid tumors. Its active ingredient is activated white
blood cells, so called dendritic cells, derived from healthy blood donors.
Intratumoral injection of these cells is expected to lead to an inflammatory
response which in turn leads to tumor-specific activation of the patient's
cytotoxic T lymphocytes.

For more information, please visit

About The Blueshirt Group

The Blueshirt Group provides capital markets expertise and strategic financial
and media relations counsel to growth companies and venture capital firms
globally. Founded in 1999, the firm has earned its reputation as a leader in
investor relations, financial communications, financial media relations and
crisis management.

For more information, please visit


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.